The UFMylation pathway is impaired in Alzheimer’s disease
2024

Impaired UFMylation Pathway in Alzheimer's Disease

Sample size: 72 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yan Tingxiang, Heckman Michael G., Craver Emily C., Liu Chia-Chen, Rawlinson Bailey D., Wang Xue, Murray Melissa E., Dickson Dennis W., Ertekin-Taner Nilufer, Lou Zhenkun, Bu Guojun, Springer Wolfdieter

Primary Institution: Mayo Clinic

Hypothesis

The UFMylation pathway is altered in the brains of individuals with Alzheimer's disease.

Conclusion

The study found significant changes in the UFMylation pathway in Alzheimer's disease brains, which are associated with pathological tau.

Supporting Evidence

  • UFM1 protein levels were significantly increased in Alzheimer's disease brains compared to controls.
  • UFMylation was correlated with pathological tau in affected brain regions.
  • UFSP2 levels were negatively correlated with UFM1 levels, indicating a potential mechanism for hyperUFMylation.

Takeaway

In Alzheimer's disease, a specific protein modification process called UFMylation doesn't work properly, which may worsen the disease.

Methodology

The study analyzed protein levels of the UFMylation pathway in brain samples from individuals with and without Alzheimer's disease using multivariable regression analyses.

Limitations

The study had a relatively small sample size, which may limit the power to detect differences.

Participant Demographics

All subjects were non-Hispanic Caucasians of European descent.

Statistical Information

P-Value

p<0.025

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s13024-024-00784-y

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication